Atlas Trials

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Clinical trial NCT03791060 · TERMINATED

Trial details

NCT number
NCT03791060
Sponsor
Beth Israel Deaconess Medical Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Necrobiosis Lipoidica Diabeticorum
Start date
2019-04-03
Primary completion
2021-01-17
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.